Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Gottesman Website

Michael M. Gottesman, M.D.

Selected Publications
1)  Gillet J, Macadangdang B, Fathke R, Gottesman M, Kimchi-Sarfaty C.
The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer. In: Cancer Gene Therapy, 2nd Edition. Volume .
Humana Press; 2009. In Press. [Book Chapter]
2)  Okabe M, Szakács G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM.
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.
Mol. Cancer Ther. 7: 3081-91, 2008. [Journal]
3)  Liang XJ, Finkel T, Shen DW, Yin JJ, Aszalos A, Gottesman MM.
SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism.
Mol. Cancer Res. 6: 1499-506, 2008. [Journal]
4)  Tsai CJ, Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM, Nussinov R.
Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima.
J. Mol. Biol. 383: 281-91, 2008. [Journal]
5)  Kimchi-Sarfaty C, Oh JM, Kim I, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM.
A "silent" polymorphism in the MDR1 gene changes substrate specificity.
Science. 315: 525-8, 2007. [Journal]
6)  Gillet J, Kimchi-Sarfaty C, Shinar S, Licht T, Lee C, Hafkemeyer P, Hrycyna C, Pastan I, Gottesman M. Templeton N, eds.
Selectable Markers for Gene Therapy. In: Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Third Edition. Volume .
Boca Raton, Florida: Taylor and Francis; 2008. In Press. [Book Chapter]
7)  Liang XJ, Yin JJ, Taylor B, Winkovitch SM, Garfield SH, Shen DW, Gottesman MM, Aszalos A.
Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell lines.
Cancer Chemother. Pharmacol. 2008. [Journal]
8)  Elbaz B, Alperovitch A, Gottesman MM, Kimchi-Sarfaty C, Rahamimoff H.
Modulation of Na+-Ca2+ exchanger expression by immunosuppressive drugs is isoform-specific.
Mol. Pharmacol. 73: 1254-63, 2008. [Journal]
9)  Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM.
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.
Annu. Rev. Pharmacol. Toxicol. 48: 495-535, 2008. [Journal]
10)  Marple A, Gottesman M, Kimchi-Sarfaty C. Hefferon K, eds.
Efficient gene therapy delivery by SV40-derived vectors. In: Virus Expression Vectors. Volume .
Trivandrum, India: Transworld Research Network; 2007. p. 247-265 [Book Chapter]
11)  Rahamimoff H, Elbaz B, Alperovich A, Kimchi-Sarfaty C, Gottesman MM, Lichtenstein Y, Eskin-Shwartz M, Kasir J.
Cyclosporin A-dependent downregulation of the Na+/Ca2+ exchanger expression.
Ann. N. Y. Acad. Sci. 1099: 204-14, 2007. [Journal]
12)  Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI, Kim IW, Jones A, Arora M, Gribar J, Gurwitz D, Gottesman MM.
Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene.
Pharmacogenomics. 8: 29-39, 2007. [Journal]
13)  Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, Ambudkar SV.
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.
Mol. Cancer Ther. 6: 3287-96, 2007. [Journal]
14)  Paterson JK, Shukla S, Black CM, Tachiwada T, Garfield S, Wincovitch S, Ernst DN, Agadir A, Li X, Ambudkar SV, Szakacs G, Akiyama SI, Gottesman MM.
Human ABCB6 Localizes to Both the Outer Mitochondrial Membrane and the Plasma Membrane.
Biochemistry. 2007. [Journal]
15)  Paterson JK, Gottesman MM.
P-Glycoprotein is not present in mitochondrial membranes.
Exp. Cell Res. 313: 3100-5, 2007. [Journal]
16)  Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.
Cancer Res. 67: 9609-12, 2007. [Journal]
17)  Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.
The sounds of silence: synonymous mutations affect function.
Pharmacogenomics. 8: 527-532, 2007. [Journal]
18)  Chen KG, Gottesman MM. Hearing VJ, Leong SP, eds.
How melanoma cells evade chemotherapy: role of transporter-dependent and independent resistance mechanisms. In: From Melanocytes to Malignant Melanoma. Volume .
Totowa, New Jersey: Humana Press; 2006. p. 591-603 [Book Chapter]
19)  Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV.
Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery.
Mol. Pharm. 3: 87-93, 2006. [Journal]
20)  Gottesman MM, Ludwig J, Xia D, Szakács G.
Defeating drug resistance in cancer.
Discovery medicine. 6: 18-23, 2006. [Journal]
21)  Liang XJ, Mukherjee S, Shen DW, Maxfield FR, Gottesman MM.
Endocytic recycling compartments altered in cisplatin-resistant cancer cells.
Cancer Res. 66: 2346-53, 2006. [Journal]
22)  Shen DW, Liang XJ, Suzuki T, Gottesman MM.
Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance.
Mol. Pharmacol. 69: 1383-8, 2006. [Journal]
23)  Nussenblatt RB, Chan CC, Wilson WH, Hochman J, Gottesman M.
International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future.
Ocul. Immunol. Inflamm. 14: 139-44, 2006. [Journal]
24)  Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F, Berens W, Wincovitch SM, Garfield SH, Leapman RD, Hearing VJ, Gottesman MM.
Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas.
Proc. Natl. Acad. Sci. U.S.A. 103: 9903-7, 2006. [Journal]
25)  Ludwig JA, Szakács G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, Caplen NJ, Fales HM, Ambudkar SV, Weinstein JN, Gottesman MM.
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
Cancer Res. 66: 4808-15, 2006. [Journal]
26)  Kimchi-Sarfaty C, Vieira WD, Dodds D, Sherman A, Kreitman RJ, Shinar S, Gottesman MM.
SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.
Cancer Gene Ther. 13: 648-57, 2006. [Journal]
27)  Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM.
Targeting multidrug resistance in cancer.
Nature reviews. Drug discovery. 5: 219-34, 2006. [Journal]
28)  Gottesman MM, Ling V.
The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research.
FEBS Lett. 580: 998-1009, 2006. [Journal]
29)  Ambudkar SV, Sauna ZE, Gottesman MM, Szakacs G.
A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1).
Trends Pharmacol. Sci. 26: 385-7, 2005. [Journal]
30)  Kimchi-Sarfaty C, Brittain S, Garfield S, Caplen NJ, Tang Q, Gottesman MM.
Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions.
Hum. Gene Ther. 16: 1110-5, 2005. [Journal]
31)  Bar-Sinai A, Bassa N, Fischette M, Gottesman MM, Love DC, Hanover JA, Hochman J.
Mouse mammary tumor virus Env-derived peptide associates with nucleolar targets in lymphoma, mammary carcinoma, and human breast cancer.
Cancer Res. 65: 7223-30, 2005. [Journal]
32)  Chen KG, Szakács G, Annereau JP, Rouzaud F, Liang XJ, Valencia JC, Nagineni CN, Hooks JJ, Hearing VJ, Gottesman MM.
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes.
Pigment Cell Res. 18: 102-12, 2005. [Journal]
33)  Liang XJ, Shen DW, Chen KG, Wincovitch SM, Garfield SH, Gottesman MM.
Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum.
J Cell Physiol. 202: 635-41, 2005. [Journal]
34)  Tarasova NI, Seth R, Tarasov SG, Kosakowska-Cholody T, Hrycyna CA, Gottesman MM, Michejda CJ.
Transmembrane Inhibitors of P-Glycoprotein, an ABC Transporter.
J Med Chem. 48: 3768-75, 2005. [Journal]
35)  Chen KG, Gottesman MM.
Useful tool to generate unidirectional deletion vectors by utilizing the star activity of BamHI in an NcoI-BamHI-XhoI cassette.
Biotechniques. 38: 198, 200, 202, 204, 2005. [Journal]
36)  Gottesman M, Licht T, Kimchi-Sarfaty C, Zhou Y, Lee C, Shoshani T, Hafkemeyer P, Hrycyna C, Pastan I. Lasic D, Templeton N, eds.
Selectable markers for gene therapy. In: Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 2nd Ed. Volume .
New York: Marcel Dekker, Inc.; 2004. p. 391-412 [Book Chapter]
37)  Liang XJ, Shen DW, Gottesman MM.
A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells.
J. Inorg. Biochem. 98: 1599-606, 2004. [Journal]
38)  Pétriz J, Gottesman MM, Aran JM.
An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein.
Current drug delivery. 1: 43-56, 2004. [Journal]
39)  Annereau JP, Szakács G, Tucker CJ, Arciello A, Cardarelli C, Collins J, Grissom S, Zeeberg BR, Reinhold W, Weinstein JN, Pommier Y, Paules RS, Gottesman MM.
Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance.
Mol. Pharmacol. 66: 1397-405, 2004. [Journal]
40)  Liang XJ, Yin JJ, Zhou JW, Wang PC, Taylor B, Cardarelli C, Kozar M, Forte R, Aszalos A, Gottesman MM.
Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells.
Exp. Cell Res. 293: 283-91, 2004. [Journal]
41)  Szakács G, Gottesman MM.
Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer.
Molecular interventions. 4: 323-5, 2004. [Journal]
42)  Liang XJ, Shen DW, Gottesman MM.
Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells.
Mol. Pharmacol. 65: 1217-24, 2004. [Journal]
43)  Shen DW, Liang XJ, Gawinowicz MA, Gottesman MM.
Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines.
Mol. Pharmacol. 66: 789-93, 2004. [Journal]
44)  Gouazé V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE, Cabot MC.
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.
Mol. Cancer Ther. 3: 633-9, 2004. [Journal]
45)  Szakács G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM.
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.
Cancer Cell. 6: 129-37, 2004. [Journal]
46)  Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM.
Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells.
Br. J. Cancer. 91: 270-6, 2004. [Journal]
47)  Kimchi-Sarfaty C, Gottesman MM.
SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy.
Current pharmaceutical biotechnology. 5: 451-8, 2004. [Journal]
48)  Szakács G, Chen GK, Gottesman MM.
The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance.
Cancer Biol. Ther. 3: 382-4, 2004. [Journal]
49)  Kimchi-Sarfaty C, Alexander NS, Brittain S, Ali S, Gottesman MM.
Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro.
BioTechniques. 37: 270-5, 2004. [Journal]
50)  Gottesman MM.
Cancer gene therapy: an awkward adolescence.
Cancer Gene Ther. 10: 501-8, 2003. [Journal]
51)  Ying YL, Shen DW, Liang XJ, Gottesman MM.
Codominance of cisplatin resistance in somatic cell hybrids.
J. Cell. Physiol. 196: 63-9, 2003. [Journal]
52)  Lee JK, Bussey KJ, Gwadry FG, Reinhold W, Riddick G, Pelletier SL, Nishizuka S, Szakacs G, Annereau JP, Shankavaram U, Lababidi S, Smith LH, Gottesman MM, Weinstein JN.
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells.
Genome Biol. 4: R82, 2003. [Journal]
53)  Sugimoto Y, Tsukahara S, Sato S, Suzuki M, Nunoi H, Malech HL, Gottesman MM, Tsuruo T.
Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
The journal of gene medicine. 5: 366-76, 2003. [Journal]
54)  Kimchi-Sarfaty C, Arora M, Sandalon Z, Oppenheim A, Gottesman MM.
High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences.
Hum. Gene Ther. 14: 167-77, 2003. [Journal]
55)  Stein WD, Robey R, Cardarelli C, Gottesman MM, Bates SE.
Low and high concentrations of the topo II inhibitor daunorubicin in NIH3T3 cells: reversible G2/M versus irreversible G1 and S arrest.
Cell Cycle. 2: 134-42, 2003. [Journal]
56)  Liang XJ, Shen DW, Garfield S, Gottesman MM.
Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines.
Cancer Res. 63: 5909-16, 2003. [Journal]
57)  Lelong-Rebel IH, Rebel G, Cardarelli CO, Pastan I, Gottesman MM.
Modulation by the ATP/GTP ratio of the phosphorylation level of P-glycoprotein and of various plasma membrane proteins of KB-V1 multidrug resistant cells.
Anticancer Res. 23: 2363-75, 2003. [Journal]
58)  Alemán C, Annereau JP, Liang XJ, Cardarelli CO, Taylor B, Yin JJ, Aszalos A, Gottesman MM.
P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.
Cancer Res. 63: 3084-91, 2003. [Journal]
59)  Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM.
P-glycoprotein: from genomics to mechanism.
Oncogene. 22: 7468-85, 2003. [Journal]
60)  Chauhan SS, Liang XJ, Su AW, Pai-Panandiker A, Shen DW, Hanover JA, Gottesman MM.
Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines.
Br. J. Cancer. 88: 1327-34, 2003. [Journal]
61)  Golin J, Ambudkar SV, Gottesman MM, Habib AD, Sczepanski J, Ziccardi W, May L.
Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux.
J. Biol. Chem. 278: 5963-9, 2003. [Journal]
62)  Licht T, Haskins M, Henthorn P, Kleiman SE, Bodine DM, Whitwam T, Puck JM, Gottesman MM, Melniczek JR.
Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow.
Proc. Natl. Acad. Sci. U.S.A. 99: 3123-8, 2002. [Journal]
63)  Kimchi-Sarfaty C, Gribar JJ, Gottesman MM.
Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system.
Mol. Pharmacol. 62: 1-6, 2002. [Journal]
64)  Kimchi-Sarfaty C, Ben-Nun-Shaul O, Rund D, Oppenheim A, Gottesman MM.
In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer.
Hum. Gene Ther. 13: 299-310, 2002. [Journal]
65)  Gottesman MM.
Mechanisms of cancer drug resistance.
Annu. Rev. Med. 53: 615-27, 2002. [Journal]
66)  Gottesman MM, Fojo T, Bates SE.
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat. Rev. Cancer. 2: 48-58, 2002. [Journal]
67)  Lee CG, Vieira WD, Pastan I, Gottesman MM.
An episomally maintained MDR1 gene for gene therapy.
Hum. Gene Ther. 12: 945-53, 2001. [Journal]
68)  Gottesman MM, Ambudkar SV.
Overview: ABC transporters and human disease.
J. Bioenerg. Biomembr. 33: 453-8, 2001. [Journal]
69)  Ambudkar SV, Rosen BP, Gottesman MM.
Workshop on ABC Transporters and Human Diseases.
Drug Resist Updat. 3: 51-54, 2000. [Journal]
70)  Liang XJ, Taylor B, Cardarelli C, Yin JJ, Annereau JP, Garfield S, Wincovitch S, Szakács G, Gottesman MM, Aszalos A.
Different roles for K+ channels in cisplatin-resistant cell lines argue against a critical role for these channels in cisplatin resistance.
Anticancer Res. 25: 4113-22, , ,. [Journal]
71)  Tarasova N, Gottesman M, Hrycyna C, Michejda C, inventor; DHHS, assignee.
Inhibition Of ABC Transporters By Transmenbrane Domain Analogs.
Patent Pending, Filed in 2000. Application No. 10/130,192. Pending [Patent]
72)  Szakacs G, Annereau J, Gottesman M, Lababidi S, Weinstein J, inventor; DHHS, assignee.
Methods for Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cells.
Patent Pending, Filed in 2004. Application No. 11/629,233. Pending [Patent]
73)  Gottesman M, Gal S, Smith S, inventor.
Cloned cDNA for Human Procathepsin L.
US Patent: 5,710,014. 1998. [Patent]
74)  Roninson I, Pastan I, Gottesman M, inventor.
Compositions of Clones Containing DNA Sequences Associated with Multidrug Resistance in Human Cells.
US Patent: 5,206,352. 1993. [Patent]
75)  Pastan I, Gottesman M, inventor; DHHS, assignee.
Gene Therapy Using Gene Fusions for Genetic or Acquired Disorders.
US Patent: 5,166,059. 1992. [Patent]
76)  Gottesman M, Pastan I, Ueda K, inventor.
Methods of Inducing Multidrug Resistance Using Human MDR1 cDNA.
US Patent: 5,928,637. 1999. [Patent]
77)  Gottesman M, Pastan I, Ueda K, Galski H, Merlino G, inventor.
Transgenic Animals Expressing a Multidrug Resistance cDNA.
US Patent: 5,849,998. 1998. [Patent]
78)  Gottesman M, Pastan I, Ueda K, inventor.
Vectors Carrying MDR1 cDNA Which Confer Multidrug Resistance on Transduced Cells.
US Patent: 5,851,819. 1998. [Patent]

This page was last updated on 1/14/2009.